Course Description
- WHO: This course provides pharmacists, student pharmacists, members of academia, industry and government with the skills necessary to develop and implement a point-of-care test and treat program for minor, nonchronic health conditions, such as influenza, Group A streptococcus, and minor, uncomplicated infections, within the framework of an established written protocol with a supervising physician.
- WHY: There is a recognized need for pharmacists to collaboratively improve patient access to care through the use of point-of-care tests and treatment.
- HOW: The course’s 20 hours of continuing education (12 hours of home study and 8 hours of live training) will cover information on the targeted disease states, the physical assessment of a patient presenting to a pharmacist, point-of-care tests and how to establish a point-of-care testing service and screening for and treatment of minor, nonchronic health conditions.
- WHEN: Please visit the upcoming trainings webpage for more information.
Program Course
Self-Study Modules (12 Hours)
Module 1: Overview of Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions
Length: 2 hours
- Identify opportunities for pharmacists to utilize testing or screening for and the treatment of minor, nonchronic health conditions within the framework of an established written protocol with a supervising physician.
- Identify the Florida requirements for a written protocol with a supervising physician.
- Describe the required elements of a written protocol between a physician and pharmacist for test and treat.
- Summarize the findings from recent collaborative research projects utilizing Point-of-Care test (POCT), protocols or Collaborative Practice Agreements (CPAs) for treatment for influenza, Streptococcus and minor, nonchronic health conditions and minor uncomplicated infections.
Module 2: Assessing Test Performance and Determining How to Use a Test Appropriately
Length: 1 hour
- Summarize the Clinical Laboratory Improvement Amendments (CLIA) as they pertain to pharmacy point-of-care testing (POCT).
- Differentiate between FDA approval and Emergency Use Authorization (EUA)
- Describe the process of obtaining a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver in Florida and regulatory requirements for pharmacies functioning as a CLIA-waived laboratory.
- List elements of Good Laboratory Practices recommended for CLIA-waived testing sites.
- Assess test performance and determine how to use a test appropriately.
Module 3: Disease States for Point-of-Care Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions or Screening for and Treatment of Minor, Nonchronic Health Conditions – Infectious Diseases
Length: 3.5 hours
- Summarize the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states or conditions.
- Influenza
- Streptococcus
- Minor, uncomplicated infections.
- Herpes Simplex Labialis (HSL) Cold Sores/Fever Blisters
- Uncomplicated cystitis
Module 4: Disease States for Point-of-Care Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions or Screening for and Treatment of Minor, Nonchronic Health Conditions – Skin Conditions
Length: 2.5 hours
- Summarize the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states or conditions.
Skin Conditions- Xerosis and Atopic Dermatitis
- Scaley Dermatosis
- Contact Dermatitis
- Insect Stings and Bites
- Lice
- Acne
- Minor Burns and Wounds
- Fungal Skin Infections
Module 5: Brief overview of other Point-of-Care Testing (no minor ailments or treatment authority)
Length: 2 hours
- Explain the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states:
- Other Respiratory infections (e.g., Respiratory Syncytial Virus, Coronaviruses)
- HIV – PrEP and PEP
- Hepatitis C Virus
- Sexually Transmitted Infections (e.g., syphilis, chlamydia, and gonorrhea)
- Conjunctivitis
- Helicobacter pylori
- Lyme Disease
- Infectious mononucleosis
Module 6: Use of Point-of-Care Tests to Promote Antimicrobial Stewardship (AS)
Length: 0.5 hours
- Define and summarize antimicrobial stewardship.
- Identify ways that pharmacists can practice stewardship and reduce antimicrobial resistance.
- Discuss how point-of care testing (POCT) can reduce unnecessary antibiotic use and contribute to a pharmacy’s stewardship program.
Module 7: Collaboration with State and Local Health Departments
Length: 0.5 hours
- Identify the role and responsibilities of state and local health departments, especially as they relate to disease surveillance and reporting.
- Outline steps to develop partnerships with state and local health departments around point-of-care testing (POCT) and treatment.
- Summarize the benefits and value of partnering with state and local health departments.
Live/Virtual Training Session (8 hours)
Module 1: Overview of Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions
Length: 0.5 hours
- Discuss key points from the self-study modules.
- Utilize testing or screening for and the treatment of minor, nonchronic health conditions within the frameworks of an established written protocol with a supervising physician.
- Describe how to implement testing or screening for and minor treatment of minor nonchronic health conditions services in your practice.
Module 2: Florida Statutes and Regulations
Length: 1 hour
- Describe the statutes and regulations applicable to testing or screening for and treatment of minor, nonchronic health conditions.
- Identify the signage, reporting, documentation and reporting requirements to patients, other health care providers and public health agencies for services provided.
- Discuss the required components in Florida law for protocol development.
- Explain the mandatory continuing education required by Florida law to provide testing or screening for and treatment of minor, nonchronic health conditions.
Module 3: Physical Assessment
Length: 1.5 hours
- Discuss the value and limitations of various physical assessment procedures, including body temperature, pulse, blood pressure, respiratory rate, cervical lymph node inspection, throat examination, and physical inspection.
- Demonstrate the procedures for conducting a systematic physical assessment and identify normal and critical findings.
- Interpret physical assessment data and recognize limitations of the data.
- Document patient assessment results.
Module 4: Specimen, Test Performance and Results
Length: 1.5 hour
- Describe the basic process of specimen collection for point-of-care testing (POCT).
- Identify a patient specimen that would be appropriate for a Clinical Laboratory Improvement Amendments (CLIA)-waived POCT.
- Describe factors that can influence test performance.
- Explain how test performance influences interpretation of test results.
- Demonstrate the technique involved for the specimen collection types discussed.
Module 5: Application of the Florida Requirements for Testing, Screening and Treatment of Minor Nonchronic Health Conditions (case studies and practical applications)
Length: 3.5 hours
- Identify specific categories of patients who the pharmacist is authorized to test or screen for and treat minor, nonchronic health conditions.
- Describe the physician’s instructions for obtaining relevant patient medical history for the purpose of identifying disqualifying health conditions, adverse reactions, and contraindications to the approved course of treatment.
- Create a process and schedule for the physician to review the pharmacist’s actions under the protocol.
- Identify a process and schedule for the pharmacist to notify the physician of the patient’s condition, tests administered, test results, and course of treatment.
- Demonstrate ability to apply for CLIA waiver.
- Develop a written protocol that includes all legally required components for legally authorized disease states and appropriate lab testing required.
- Apply test and treat protocol information to patient-specific cases based on common pharmacy-based patient interactions.
Additional Information
Agenda
CE Info
Developer Bios
Disclaimers
Host a Training
Upcoming Trainings